itolizumab Archives - Express Pharma

Biocon starts clinical study to evaluate efficacy of Itolizumab

Biocon Biologics initiates clinical study for Itolizumab in Lupus Nephritis

Biocon Q1FY22 revenue at Rs 1,808 crores, up six per cent

SEC asks Biocon to submit safety, mortality data for Itolizumab

Health ministry decides against including Itolizumab in clinical management protocols for COVID-19

Biocon presents key Insights into clinical study that enabled DCGI approval of Itolizumab

Biocon to launch drug for COVID-19 patients; priced at Rs 8,000 per vial

DCGI approves Itolizumab for restricted emergency use in COVID-19 treatment

Biocon and Equillium expand exclusive licensing agreement for Itolizumab to include Australia and New Zealand